Stefania Scala

Naples, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 100 publications

CXCR4, CXCR7 and PBRM1 are responsible for everolimus and cabozantinib resistance in human renal cancer cells.

CXCR4, CXCR7 and PBRM1 are responsible for everolimus and cabozantinib resistance in human renal cancer cells.

Journal: Cell death discovery

Published: July 30, 2025

[225Ac]Ac-PSMA-617 production method: development of an efficient and reproducible radiolabelling process for establish a clinical routine production.

[225Ac]Ac-PSMA-617 production method: development of an efficient and reproducible radiolabelling process for establish a clinical routine production.

Journal: EJNMMI radiopharmacy and chemistry

Published: February 14, 2025

Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatin + paclitaxel/avelumab (MITO-END3 trial).

Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatin + paclitaxel/avelumab (MITO-END3 trial).

Journal: Cancer immunology, immunotherapy : CII

Published: January 16, 2025

Balancing immunotherapy and corticosteroids in cancer treatment: dilemma or paradox?

Balancing immunotherapy and corticosteroids in cancer treatment: dilemma or paradox?

Journal: The oncologist

Published: August 07, 2024

The CXCR4 antagonist R54 targets epithelial-mesenchymal transition (EMT) in human ovarian cancer cells.

The CXCR4 antagonist R54 targets epithelial-mesenchymal transition (EMT) in human ovarian cancer cells.

Journal: PloS one

Published: August 02, 2024

Comprehensive structural investigation of a potent and selective CXCR4 antagonist via crosslink modification.

Comprehensive structural investigation of a potent and selective CXCR4 antagonist via crosslink modification.

Journal: European journal of medicinal chemistry

Published: July 21, 2024

Neoadjuvant Versus Adjuvant Systemic Therapy in Breast Cancer: A Matched Case-control Study.

Neoadjuvant Versus Adjuvant Systemic Therapy in Breast Cancer: A Matched Case-control Study.

Journal: Anticancer research

Published: May 24, 2024

Disulfide bond replacement with non-reducible side chain to tail macrolactamization for the development of potent and selective CXCR4 peptide antagonists endowed with flanking binding sites.

Disulfide bond replacement with non-reducible side chain to tail macrolactamization for the development of potent and selective CXCR4 peptide antagonists endowed with flanking binding sites.

Journal: European journal of medicinal chemistry

Published: May 20, 2024

KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer.

KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 08, 2024

CXCL12-loaded-hydrogel (CLG): A new device for metastatic circulating tumor cells (CTCs) capturing and characterization.

CXCL12-loaded-hydrogel (CLG): A new device for metastatic circulating tumor cells (CTCs) capturing and characterization.

Journal: Heliyon

Published: September 26, 2023

Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients.

Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients.

Journal: British journal of cancer

Published: September 20, 2023

Oligo-metastatic neoPlasms from the gastro-intestinal tract: iDentIfiCaTIon of cliNical and molecular drivers: the PREDICTION study.

Oligo-metastatic neoPlasms from the gastro-intestinal tract: iDentIfiCaTIon of cliNical and molecular drivers: the PREDICTION study.

Journal: BMC cancer

Published: July 05, 2023

Showing 1-12 of 100

Last Updated: 09/26/2026